期刊文献+

肺癌E-cadherin基因启动子CpG岛甲基化的研究 被引量:5

The Study of CpG Island Methylation of E-cadherin Gene Promoter in Lung Cancer
下载PDF
导出
摘要 目的检测肺癌组织、相应的癌旁组织及正常肺组织中E-cadherin基因启动子CpG岛甲基化水平,探讨肺癌的发病机制。方法采用甲基化特异性PCR技术检测22例肺癌组织、相应的癌旁组织和9例正常肺组织中E-cad-herin基因启动子CpG岛甲基化水平。结果肺癌中E-cadherin基因启动子CpG岛完全甲基化率为13.6%(3/22),部分甲基化率为27.3%(6/22),总甲基化率为40.9%(9/22),显著高于相应癌旁组织中该基因的甲基化率9.1%(2/22)。9例正常肺组织中该基因未发生甲基化。此外,E-cadherin基因启动子CpG岛异常甲基化与患者性别、年龄无关,甲基化的发生率随着肿瘤的分期早晚有上升的趋势。结论E-cadherin基因启动子CpG岛的异常甲基化是肺癌发生中的常见分子事件,可能参与了肺癌的发生发展过程。 Objective To detect the CpG island methylation status of E-cadherin gene promoter in lung cancer , paired adjacent cancerous tissues and normal lung tissues, and to explore the mechanism of lung carcinogenesis. Methods The tissue specimens from 22 cases of lung cancer,adjacent cancerous tissues and 9 cases of normal lung tissues were examined CpG island methylation of E-cadherin gene promoter by methylation specific PCR. Results The positive rate of E-cadherin hypermethylation in lung tumor tissues was significantly higher than that in the adjacent cancerous tissues(40.9% vs 9.1%, P 〈0.05 ). The incidence of promoter hypermethylation was not examined in 9 normal lung tissues. Anymore, hypermethylation of E-cadheHn was not associated with gender and age. The incidence ratio of promoter hypermethylation of E-cadherin is ascendant with the carcinomas becoming much later. Conclusion Methylation of E-cadherin gene is a common molecule event in lung cancer and play a role in the development and progression of lung cancer.
出处 《实用癌症杂志》 2007年第4期357-359,共3页 The Practical Journal of Cancer
基金 新疆伊犁哈萨克自治州科技攻关和重点科技项目(YZ200601025) 徐州医学院附属医院课题(2006022)
关键词 肺癌 上皮细胞钙粘蛋白 CPG岛 甲基化 甲基化特异性聚合酶链反应 Lung cancer E-cadherin CpG islands Methylation Methy lation specific(MSP)
  • 相关文献

参考文献12

二级参考文献100

  • 1Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol,2005,17 ( 1 ) : 55-60.
  • 2Das PM,Singal R. DNA methylation and cancer, J Clin Oncol,2004,22(22) : 4632-4642.
  • 3Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) ,2004,229(10) : 988-995.
  • 4Brown R,Strathdee G. Epigenomics and epigenetic therapy of cancer.Trends Mol Med,2002,8(4 Suppl) : S43-48.
  • 5Ushijima T. Detection and interpretation of altered methylation patterns in cancer ceils. Nat Rev Cancer,2005,5 (3) : 223-231.
  • 6Goffin J, Eisenhauer E. DNA methyhransferase inhibitors-state of the art. Ann Oncol,2002,13(11) : 1699-1716.
  • 7Abe M, Okochi E, Kuramoto T, et al. Cloning of the 5'upstream region of the rat p16 gene and its role in silencing. Jpn J Cancer Res,2002,93(10) : 1100-1106.
  • 8Miyakura Y,Sugano K, Konlshi F, et al, Extensive methylation of hM-LH1 promoter region predominates in proximal colon cancer with microsatellite instability, Gastroenterology ,2001,121 (6) : 1300-1309.
  • 9Yan PS, Shi H, Rahmatpanah F, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res,2003,63(19) : 6178-6186.
  • 10Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 2003,349 ( 21 ) : 2042-2054.

共引文献53

同被引文献71

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部